Released : Jun 30, 2014

Tiziana Life Sciences PLC ("Tiziana" or the "Company")

Licensing agreement to develop stem cell based breast cancer diagnostic

Building an oncology franchise

London, 30 June 2014 - Tiziana Life Sciences (AIM: TILS) ("Tiziana"), the UK biotechnology company, today announces that it has entered into an exclusive license agreement with TTFactor S.r.l. ("the Licensor", acting on behalf of the FIRC (the Italian Foundation for Cancer Research) Institute for Molecular Oncology (IFOM), and the European Institute of Oncology (IEO)), covering the use of twenty defined stem cell markers (the "TOP 20") for patient stratification in breast cancer.

The TOP 20 model is a gene expression signature capable of predicting disease aggressiveness and prognosis in breast cancer patients. It is different from all other signatures available today because it is derived from cancer stem cells and therefore it predicts cancer behaviour based on its stem cell content.  The TOP 20 genes have been defined based on published expression profiles of breast stem cells, and further selected based on their levels of expression and likelihood of reduction into practice for patient stratification in breast cancer.

The inventor of the TOP 20 model, Professor Pier Paolo Di Fiore, a physician and specialist in molecular oncology and cell biology, is a consultant to Tiziana and a member of Tiziana's Scientific Advisory Board.

Under the terms of the licensing agreement, Tiziana will pay the Licensor €600,000 over 4 years to fund research to create or enhance technologies to assist in the development and commercialization of products and services derived from the TOP 20 genes. In return for an exclusive license to patents on the TOP20 genes, Tiziana will pay the Licensor inter alia a royalty rate of 1.5% based on commercial sales of any products developed under the license agreement.

Gabriele Cerrone, Executive Chairman of Tiziana, said: "We are very excited to be developing a diagnostic test with IEO, one of Europe's leading breast cancer institutes. This agreement gives us access to cutting edge stem cell technology as the TOP 20 model is synergistic with our existing therapeutic focus and enables us to enhance our franchise in breast cancer treatment.

"Stem cells are the "engine" of cancer and, therefore, laboratory tests based on stem cells are more likely to be helpful in patients' management both from the diagnostic and therapeutic viewpoint. Stratification of patients according to their clinical prognosis is an important goal in cancer research as it allows oncologists to better personalize patient treatment."

Professor Pier Paolo Di Fiore said: "I believe that Tiziana's elite and world-renowned oncology researchers provide the perfect platform to commercialise the TOP 20 model.  I look forward to working closely with Dr Napoleone Ferrara, Dr Riccardo Dalla-Favera and the rest of the Tiziana team to offer this new diagnostic test for breast cancer patients."

Notes to Editors

Tiziana Life Sciences is a leading UK biotechnology company whose mission is to discover and develop novel molecules that impact human disease in the area of oncology, with a particular focus on metastatic cancers. 
For more information go to www.tizianalifesciences.com

TTFactor is the technology transfer company of the European Institute of Oncology and the FIRC Institute of Molecular Oncology with the mission of supporting researchers and clinicians in evaluating the commercial potential of their research, promoting relationships with industry to foster further potential industrial applications. Typical TTF activities include patent filing, licensing, sponsored research agreements and spin off creation. Additional information can be found at www.ttfactor.com

European Institute of Oncology (IEO) is a non-profit "Comprehensive Cancer Center" integrating clinical activity with research and training. It represents an innovative model for health service and advanced research in oncology at a global level. Aligned with the most advanced international oncology centers standards, the European Institute of Oncology has developed a fully integrated model providing prevention, diagnosis, health education, training and research, a model achieved through a deep cross-talk between clinical scientific research and an innovative management, in a context of continuous attention to the quality of the service delivered to patients.

IFOM - Founded in 1998 by FIRC (the Italian Foundation for Cancer Research), the Institute of Molecular Oncology (IFOM) is a cancer research institute focused on the study of cancer formation and development at molecular level, with a view to a rapid transfer of results from bench to bedside.

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Tiziana Life Sciences PLC via Globenewswire

HUG#1806210